Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
AUTHORS
Hung
AM ,
Roumie
CL ,
Greevy
RA ,
Grijalva
CG ,
Liu
X ,
Murff
HJ ,
Ikizler
TA ,
Griffin
MR ,
. Clinical journal of the American Society of Nephrology : CJASN. 2016 11 8; ().
- PMID: 27827311 [PubMed].
ABSTRACT
Diabetes is the leading cause of ESRD. Glucose control improves kidney outcomes. Most patients eventually require treatment intensification with second-line medications; however, the differential effects of those therapies on kidney function are unknown.
Diabetes is the leading cause of ESRD. Glucose control improves kidney outcomes. Most patients eventually require treatment intensification with second-line medications; however, the differential effects of those therapies on kidney function are unknown.
Tags: Alumni Publications 2016